Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Rani Therapeutics Holdings, Inc. (RANI)

Rani Therapeutics Q3 revenue $1.7 million; net loss rises to $8.8 million

Mixed Impact 3 of 5 earnings

Rani Therapeutics reported third-quarter 2026 results with contract revenue of $1.7 million, up from none a year earlier, mainly from its Chugai collaboration. Net loss rose to $8.8 million from $7.9 million as research and development and general and administrative expenses increased, and cash, cash equivalents and marketable securities fell to $45.3 million, which the company says will fund operations at least through the end of 2027.

Key points

  • Contract revenue was $1.7 million for the quarter ended September 30, 2026, versus no contract revenue a year earlier.
  • Net loss attributable to Rani was $7.7 million, compared with $5.4 million in the prior-year quarter; net loss per Class A share was $0.04, versus $0.12.
  • Cash, cash equivalents and marketable securities were $45.3 million at September 30, 2026, down from $53.4 million at June 30, 2026.
  • In October 2026 the RaniPill platform was accepted into the FDA's Emerging Technology Program; RT-114 expansion cohort data are expected by the end of 2026.

The filing

CompanyRani Therapeutics Holdings, Inc. (RANI)
Form8-K, current report
Filed with the SECNov 9, 2026, 5:00 PM ET
Accession number0001193125-26-453804

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 5:11 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.